Photo: KATERYNA KON/SCIENCE PHOTO LIBRARY/Getty
The U.S. Food and Drug Administration (FDA) recently approved a new combination of chemotherapy and immunotherapy for people with advanced non-small cell lung cancer who are ineligible for surgery or chemoradiation and whose tumors do not carry any gene mutations that can be targeted with other highly specific drugs. Jeffrey G. Schneider, MD, chief of hematology and oncology at Perlmutter Cancer Center at 嘿嘿视频 Hospital鈥擫ong Island, tells SurvivorNet that combining the immunotherapy, called Libtayo, with chemotherapy enables people with advanced lung cancer to have 鈥渢wo shots鈥 at an effective therapy at once.
鈥淭he benefits of this therapy are very meaningful because the addition of immunotherapy adds significantly to both quality and quantity of life.鈥 says Dr. Schneider, also an associate professor in the at NYU Long Island School of Medicine. 鈥淢oreover, it is safe. There is much more chance that a patient will die because they did not get this combination than because they did.鈥
Read more from .
